Navigation Links
ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)

LEUVEN, Belgium and LUND, Sweden, January 26 /PRNewswire-FirstCall/ -- ThromboGenics NV (EURONEXT:THR) and BioInvent International AB (OMXS:BINV) announce today that they have received a technology transfer success fee of EUR5 million from Roche under the terms of their strategic alliance for the novel anti-cancer antibody, TB-403. The payment has been triggered by the successful transfer and implementation of technology and process development to Roche in relation to the ongoing clinical development of TB-403.

The TB-403 strategic alliance with Roche was signed in June 2008. Under the terms of this ongoing agreement, ThromboGenics and BioInvent received an initial upfront payment of EUR50 million, with the potential of milestone payments of up to EUR450 million following completion of a series of development and commercial milestones, as well as double digit royalties on future sales. ThromboGenics, which discovered TB-403, receives 60% and BioInvent 40% of the revenue from the deal.

Under the terms of the agreement, Roche is responsible for all development costs for TB-403, including the completion of the Phase Ib trial currently being run by BioInvent and ThromboGenics.

TB-403 (anti-PlGF) is a humanized monoclonal antibody that blocks the formation of the new blood vessels required by solid tumours to support growth. PlGF is a homologue of VEGF, and clinical evidence suggests that it plays a role in the angiogenesis of malignant tissue, and does not affect normal tissue angiogenesis.

Patrik De Haes, CEO of ThromboGenics, commented, "We are very pleased to be able to make this announcement today. The fact that we have been able to achieve the goal that has triggered this payment from Roche so quickly highlights the excellent working relationship that has developed between all parties in this important strategic alliance. We are looking forward to the results of the current Phase Ib clinical trial with TB-403, and in assisting Roche in paving the way for the broader clinical development program with this unique anti-cancer agent."

Svein Mathisen, CEO of BioInvent, said, "We are delighted to receive the success fee associated with this important event in our key strategic alliance with Roche. A good momentum has been achieved in the collaboration, and the value of the program continues to be enhanced. TB-403 has the potential to become a significant new treatment for cancer and we are pleased to be supporting Roche in its progress towards commercialisation."

Legal disclaimer

This press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Notes to Editors:

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product Microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at

About BioInvent

BioInvent International AB, listed on the OMX Nordic Exchange Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances around these product candidates and is developing them in collaboration with partners including Genentech, Roche and ThromboGenics.

These projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abello, Bayer HealthCare, ImmunoGen, OrbusNeich, Sanofi-Aventis, UCB and XOMA for antibody discovery. More information is available at

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.00 a.m. CET, on 26 January, 2009.

    For further information, please contact:

    ThromboGenics NV

    Patrik De Haes
    Chief Executive Officer
    Tel: +32(0)16-75-13-10

    Stuart Laermer
    Chief Business Officer
    Tel: +1-212-201-0920

    Citigate Dewe Rogerson
    Amber Bielecka, David Dible, Nina Enegren
    Tel: +44(0)207-638-95-71

    BioInvent International AB

    Svein Mathisen
    President & CEO
    Tel:    +46(0)46-286-85-67
    Mobile: +46(0)708-97-82-13

    Cristina Glad
    Executive Vice President
    Tel:    +46(0)46-286-85-51
    Mobile: +46(0)708-16-85-70

    College Hill (media enquiries)
    Holly Griffiths, Katja Stout, John McIntyre
    Tel: +44(0)20-7457-2020

    ThromboGenics NV
    Gaston Geenslaan 1
    B-3001 Leuven
    Tel: +32(0)16-75-13-10

    BioInvent International AB (publ)
    Co. reg. No. 556537-7263
    Address: Solvegatan 41
    Mailing address: SE-223 70 LUND
    Tel: +46(0)46-286-85-50

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
4. PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications
5. Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
6. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
7. PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.
8. Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
9. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
10. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
11. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
Post Your Comments:
(Date:10/9/2015)... Der " JCA-Mauvernay Award   2015 ... Dr.   Junko Takita    --> Der ... an Dr.   Yutaka Kondo und Dr.   Junko ... JCA-Mauvernay Award   2015 " geht an Dr.   ... ™ , das weltweit tätige Schweizer Biopharmazieunternehmen, wird am 10. Oktober ...
(Date:10/8/2015)... 2015  Ardelyx, Inc. (NASDAQ: ARDX ), ... cardio-renal diseases, today announced that clinical data for ... presented at the 2015 American College of Gastroenterology ... of sustained response in IBS-C patients enrolled in ... 2 trial. The meeting will be held in ...
(Date:10/8/2015)... , Oct. 8, 2015  Following months of investigation, ... in the nation alleging that the anticoagulant Xarelto,s recommended dosage ... results. Philadelphia on behalf of ... ischemic stroke because the drug didn,t work as the manufacturer ... numerous other suits shortly on behalf of clients from across ...
Breaking Medicine Technology:
... Company,(NYSE: LLY ), strongly disagrees with the ... Attorney General Richard Blumenthal,in a news release issued ... of the release is a disservice to patients ... life-threatening disease.,Specifically, the news release contained no acknowledgement ...
... Pharmaceuticals,Inc. (Amex: ANX ) announced today that ... of ANX-510, CoFactor(R), for the treatment of,advanced breast ... 2008,American Society of Clinical Oncology (ASCO) Annual Meeting, ... in Chicago, IL., The poster presentation entitled ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... Isabel Healthcare will participate in the Cerner Health ... the release of the Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel ... that assist healthcare providers and consumers to potentially reduce the chance of error. The ...
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, entitled ... To Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The announcement ... with a celebratory gala on October 1st. , Many of the features of ...
(Date:10/9/2015)... California (PRWEB) , ... October 09, 2015 , ... ... Osteopathic Medicine of the Pacific Associate Dean for Graduate Medical Education J. Michael ... of the Year Award. Finley was selected for his impact on graduate medical ...
(Date:10/9/2015)... Los Angeles, CA (PRWEB) , ... October 09, 2015 , ... ... awareness for breast cancer victims, survivors, and the ongoing effort to find a cure. ... patients another outlet for helping women in need. With their Bra Collection Campaign, Beverly ...
(Date:10/9/2015)... ... October 09, 2015 , ... A new health tool that helps identify if ... online ( ) – just in time for the cold and flu season, ... However, for many in the U.S., the real start of cold/flu season is the ...
Breaking Medicine News(10 mins):
... ... medical journal Osteoporosis International found that women taking AdvaCAL® calcium had the highest bone ... 32 studies involved 3,169 postmenopausal women, 79 skeletal measures and 7 different types of ... ...
... ... Dermatologist settled in Dubai, received the very prestigious ,HIND RATTAN AWARD, this ... Rattan was presented at a ceremony in connection with the yearly International ... Heavy Industries and Public Enterprises, Government of India. Dr. Mehta was awarded ...
... ... IL based management consulting and technology firm, today announced it will merge ... Gold Certified Partner, effective January 1, 2010. Logan Consulting is ... America, Europe and Asia since 1992. Under the new structure, ...
... , ... Omnetics Connector Corporation, the leading manufacturer of miniature high-rel connectors, is utilizing their ... , ... MN (Vocus) January 29, 2010 -- Omnetics Connector Corporation, the leading manufacturer of ...
... ... Vemma Nutrition Company launches Vemma ... or other sports drinks, Vemma THIRST goes beyond hydration by ... minerals, while replenishing the body with necessary electrolytes, specialized carbohydrates ...
... , , Majority of Mississippi ... Jan. 28 The following is a statement by ... Consumer Healthcare Products Association (CHPA): , "Today, the Mississippi ... that, if it becomes law, will greatly limit how cold and ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: